Clinical Trial ID: NCT05100862
A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Status
Open
Conditions
Other
Phases
III (Cancer Prevention)
Main Investiagtor
Norkin, Maxim
Practice
Lymphoma
Scope
National
Participating Institutions
Baptist MD Anderson Cancer Center
Nct ID Number
NCT05100862
Secondary Trial ID Number
BGB-3111-308
Keywords
Treatment